In the evolving landscape of cancer therapeutics, claudin proteins have emerged as compelling targets with transformative potential for treating a variety of solid tumors. Claudins, a family of transmembrane proteins integral to maintaining epithelial cell polarity and the integrity of tight junctions, play pivotal roles far beyond their initial characterization in healthy tissues. Recent advances underscore their aberrant expression in numerous cancers, linking them intricately to tumor biology in ways that open unprecedented avenues for intervention.
Claudins function as gatekeepers of cellular barriers, ensuring selective permeability and maintaining cellular architecture within epithelial layers. Their dysregulation, often manifesting as overexpression in solid tumors, not only disrupts this critical barrier function but also profoundly influences oncogenic signaling pathways. This disruption has been shown to drive key aspects of cancer progression, including tumor growth, epithelial-to-mesenchymal transition (EMT), acquisition of stem cell-like properties, and resistance to therapeutic agents, each cornerstone processes in the lethal evolution of malignancies.
The detection of heightened claudin levels across diverse tumor types encapsulates their promise as both biomarkers and therapeutic targets. Indeed, the correlation between specific claudin isoform expression patterns and tumor subtype, grade, and patient prognosis refines their utility in precision oncology strategies. Claudin 18.2, for example, has gained remarkable attention given its tumor-selective expression and the successful clinical development of a monoclonal antibody targeting this isoform, marking a watershed moment in claudin-targeted therapy.
Therapeutic exploitation of claudins capitalizes on their extracellular domains, which protrude from the cell surface, rendering these proteins accessible to monoclonal antibodies and antibody-based conjugates. The recent approval of therapeutic antibodies against claudin 18.2 has set the stage for an array of innovative biologic modalities, including antibody-drug conjugates (ADCs), bispecific and trispecific antibodies, as well as emerging chimeric antigen receptor (CAR) T cell therapies aimed at various claudin family members. These approaches promise to wield unprecedented precision in targeting tumors while sparing normal tissues.
The molecular mechanisms underpinning claudin-mediated tumorigenesis are complex and multifaceted. Dysregulated claudin expression modulates intracellular signaling cascades that regulate cell proliferation and survival, such as the AKT and MAPK pathways. Furthermore, claudins orchestrate dynamic changes in the tumor microenvironment, influencing immune cell infiltration, fibrosis, and the extracellular matrix. These biological effects underscore the importance of claudins far beyond structural roles, positioning them as active participants in cancer pathophysiology.
One of the defining challenges and opportunities in claudin-targeted therapy lies in the heterogeneity of claudin expression across cancer types and within tumor subpopulations. A nuanced understanding of isoform-specific roles and expression patterns is crucial for optimizing therapeutic windows and minimizing off-target toxicity. This calls for integrated biomarker-driven patient selection, leveraging advanced molecular profiling technologies to stratify patients who are most likely to derive benefit from claudin-directed agents.
On the technological frontier, the development of CAR T cells engineered to recognize claudin epitopes heralds a novel frontier in adoptive cell therapy. These cellular therapies are designed to circumvent limitations of conventional antibody treatments, offering potent, sustained anti-tumor activity through direct immune system engagement. Early-phase clinical trials exploring claudin-specific CAR T cells for solid tumors have demonstrated promising safety and efficacy profiles, igniting hope for this modular immunotherapeutic class.
Targeting the intracellular domains of claudins and their downstream signaling pathways represents an innovative approach, potentially circumventing extracellular heterogeneity and enhancing therapeutic durability. Small molecule inhibitors or peptides designed to disrupt protein-protein interactions within tight junction complexes could modulate tumor-promoting signals tethered to claudins. This layer of intervention addresses the intracellular machinery that facilitates tumor aggressiveness, adding a new dimension to the claudin targeting repertoire.
From an immuno-oncology perspective, claudins influence the immune milieu surrounding tumors, affecting immune evasion and response to immunotherapies. Aberrant claudin expression can modulate the recruitment and function of immune effector cells, raising the possibility that co-targeting claudins alongside immune checkpoints may synergistically enhance anti-tumor immunity. This intersection between barrier proteins and immune modulation is an exciting avenue warranting deeper exploration.
The evolving clinical development pipeline reflects the breadth of therapeutic modalities harnessed to exploit claudin dysregulation. Monoclonal antibodies targeting claudin 18.2 have reached regulatory approval, validating the concept and yielding patient benefits in gastric and pancreatic cancers. Numerous clinical trials are ongoing for claudin-directed ADCs, bispecific antibodies, and CAR T cells, evaluating safety, efficacy, and optimal combination regimens against various solid tumors including lung, breast, and colorectal cancers.
Integration of claudin-targeting strategies into clinical practice necessitates robust companion diagnostics capable of sensitive and specific isoform detection. Techniques such as immunohistochemistry, RNA in situ hybridization, and next-generation sequencing are instrumental in characterizing claudin expression landscapes. This diagnostic backbone ensures aligned patient selection and informs therapeutic decision-making, facilitating precision medicine paradigms in oncology.
Understanding resistance mechanisms to claudin-targeted therapies remains imperative to sustain durable clinical responses. Tumor plasticity, including claudin isoform switching and modulation of junctional complexes, could compromise therapeutic efficacy. Research endeavors aimed at dissecting these resistance pathways will enable the rational design of combination therapies to overcome adaptive tumor escape.
As we step into a new era of targeted oncology, claudins embody the multifaceted potential of tight junction proteins in cancer therapy. Their unique biology—bridging structural integrity, signaling, and immune interactions—positions them at a nexus ripe for therapeutic exploitation. Continued interdisciplinary research and clinical innovation will chart the course toward integrating claudin-targeting agents as mainstays of cancer treatment.
In summary, claudin proteins represent an emerging frontier in solid tumor therapeutics with broad implications across cancer subtypes. Advances in antibody engineering, cellular therapies, and molecular targeting strategies underscore the translational momentum in this field. Harnessing claudin biology promises to refine patient-specific interventions, offering hope for improved outcomes in malignancies historically refractory to conventional treatments.
As clinical trials expand and mechanistic insights deepen, the convergence of biology, technology, and clinical medicine will unlock the full potential of claudin-targeted therapies. This paradigm exemplifies the power of precision oncology—transforming fundamental understanding into tangible, life-extending treatments for patients facing the formidable challenge of solid tumors.
Subject of Research: Claudin proteins as therapeutic targets in solid tumors.
Article Title: Claudin proteins as emerging therapeutic targets for solid tumours.
Article References: Saviano, A., Toso, A., Klempner, S.J. et al. Claudin proteins as emerging therapeutic targets for solid tumours. Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00913-3
Image Credits: AI Generated
